ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎÏ·ÖÐɽҽѧԺÍõº£º£ºÓ½ÌÊÚÍŶӹØÓÚÈéÏÙ°©Ï¸°û¶Ô»¯ÁÆÄÍÒ©»úÖÆµÄÑо¿ÔÚAutophagy½ÒÏþ

¸å¼þȪԴ£º£ºÖÐɽҽѧԺ ±à¼­£º£ºÖ£Áú·É¡¢¡¢¡¢Íõ¶¬Ã· ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Íõº£º£ºÓ£©¿ËÈÕ£¬£¬£¬ÖÐɽҽѧԺÍõº£º£ºÓ½ÌÊÚÍŶÓ¡¢¡¢¡¢ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔºÑîÊñá°Ñо¿Ô±ÍŶÓÏàÖúÔÚAutophagy (2020 IF:16.016)½ÒÏþÌâ¡°Adaptor SH3BGRL drivesautophagy-mediated chemoresistance through promoting PIK3C3 translation andATG12 stability in breast cancers¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬¸ÃÑо¿Õ¹ÏÖÁËÒ»¸öС·Ö×ÓÌÖÂÛÂѰ×SH3BGRL¿ÉÒÔͨ¹ýÁ¬ÏµºËÌÇÌåÂѰ×Ôö½ø×ÔÊÉÏà¹Ø»ùÒòµÄÂѰ׷­ÒëЧÂÊ£¬£¬£¬´Ó¶øÔö½øÈéÏÙ°©Ï¸°ûµÄÖжÈ×ÔÊɶøµ¼ÖÂÈéÏÙ°©Ï¸°û¶Ô»¯ÁÆÄÍÒ©µÄ»úÖÆ¡£¡£¡£

ϸ°ûͨ¹ý×ÔÊÉ¿ÉÒÔ½µ½âϸ°ûÄÚ³¤ÊÙÃüÂѰס¢¡¢¡¢ÂѰ׾ۺÏÎïÒÔ¼°ÊÜËðϸ°ûÆ÷À´µ÷¿ØºÍά³Öϸ°ûµÄÎÈ̬£¬£¬£¬Ëü»¹¿ÉÒÔͨ¹ýÏÞÖÆÑ×Ö¢¡¢¡¢¡¢É¨³ýÓж¾µÄδÕÛµþÂѰף¬£¬£¬³ýÈ¥ÌìÉúÑÄÐÔÑõ´Ø£¨¿ÉËðº¦DNA£©µÄÊÜËðÏßÁ£ÌåÀ´ÒÖÖÆÖ×ÁöÔçÆÚÐγɡ£¡£¡£Ò»µ©Ê§È¥ÕâÖÖÑÚ»¤ÐÔ²½·¥½«´Ùʹ°©Ö¢±¬·¢£¬£¬£¬Ö×Áöϸ°ûÖеÄÊʶÈ×ÔÊÉÍùÍùÔö½øÖ×Áöϸ°ûµÄ´æ»îºÍ¿¹Ä湦Ч£¬£¬£¬½ø¶øµ¼ÖÂÖ×Áöϸ°ûÄÍÒ©£¬£¬£¬ÓÉ´Ë˵Ã÷ϸ°û×ÔÊÉÔÚÖ×Áö±¬·¢¡¢¡¢¡¢¿ªÕ¹Àú³ÌÖоßÓÐÁ½ÃæÐÔ¡£¡£¡£ÏÖÔÚ£¬£¬£¬¹ØÓÚÖ×Áöϸ°ûÖÐËù±£´æµÄÄÚÔÚµÄ×ÔÊɱ¬·¢ÆøÖÆ»òÕßÖ±½ÓµÄÇý¶¯»ùÒòÈÔÈ»»¹ºÜ²»ÇåÎú¡£¡£¡£

ÔÚÕâÏîÑо¿ÊÂÇéÖУ¬£¬£¬Ñо¿ÍŶÓÊ×ÏÈ»ùÓÚÁÙ´²ÑùÌìÖ°Îö·¢Ã÷SH3BGRLÎÞÂÛÊÇÔÚRNAˮƽÕÕ¾ÉÂѰ×ˮƽÔڸߴï40-60%µÄÈéÏÙ°©Ñù±¾Öи߱í´ï£¬£¬£¬²¢ÇÒÓ뻼ÕߵIJ»Á¼Ô¤ºóºÍ»¯ÁÆÄÍÒ©Ïà¹Ø¡£¡£¡£»ùÓÚSH3BGRLÊÇÒ»¸ö¼òÆÓµÄÌÖÂÛÂѰ×ÌØÕ÷£¬£¬£¬Ñо¿Õßͨ¹ýÂѰ׻¥×÷µÄÖÊÆ×ÆÊÎö·¢Ã÷SH3BGRLÔÚÖ×Áö×éÖ¯ÑùÆ·ºÍϸ°ûÖоù¿ÉÒÔÁ¬Ïµ´ó×ÚºËÌÇÌåÑÇ»ùÂѰף¬£¬£¬½ø¶øÍ¨¹ý¶à¾ÛºËÌÇÌåÆ×£¨poly-ribosome profiling£©Á¬ÏµRNA²âÐòÆÊÎö·¢Ã÷£¬£¬£¬SH3BGRL±í´ïת±ä¿ÉÒÔÒýÆðÆÕ±éµÄmRNA·­ÒëЧÂʸı䣻Ñо¿½øÒ»²½·¢Ã÷£¬£¬£¬ÔÚ·­Òë¸Ä±äµÄ»ùÒòµ±ÖУ¬£¬£¬Óë×ÔÊÉÆðʼÏà¹Ø»ùÒòPIK3C3µÄ·­ÒëЧÂʼ±¾çÔöÌí¡£¡£¡£±ðµÄ£¬£¬£¬SH3BGRL»¹¿ÉÒÔÁ¬ÏµÁíÒ»¸ö×ÔÊÉÆðʼ»ùÒòÏà¹ØÂѰ×ATG12£¬£¬£¬ÒÖÖÆÆä·ºËØ»¯½µ½â£¬£¬£¬´Ó¶øÔö½øÁËÖ×Áöϸ°ûµÄ×ÔÊÉˮƽ¡£¡£¡£µ±ÔÚSH3BGRL¹ý±í´ïµÄϸ°ûÖÐͨ¹ýÇóýPIK3C3»òATG12¿ÉÒÔ×èÖ¹SH3BGRLÒýÆðµÄϸ°û×ÔÊÉÒÔ¼°Ö×Áöϸ°û¶ÔdoxorubicinµÈ»¯ÁÆÒ©ÎïµÄÄÍÒ©ÐÔ£»¶øÇýµSH3BGRL¿ÉÒÔ½µµÍϸ°ûµÄ×ÔÊÉˮƽ£¬£¬£¬ÔöÌí¶ÔÕâЩ»¯ÁÆÒ©ÎïµÄÃô¸ÐÐÔ¡£¡£¡£

±¾Ñо¿Ê×´Î֤ʵһ¸öС·Ö×ÓÅþÁ¬ÂѰ׿ÉÒÔͨ¹ýÁ¬Ïµµ½ºËÌÇÌ帴ºÏÎïÀ´µ÷ÀíºËÌÇÌå¶ÔmRNA·­ÒëµÄЧÂÊÌØÕ÷¶øÔö½øÖ×Áöϸ°ûÖÐÓëÖ×Áöϸ°û×ÔÊɱ¬·¢Ïà¹Ø»ùÒòÔÚ·­ÒëˮƽÉϵÄÉϵ÷±í´ï£¬£¬£¬Îª½øÒ»²½Ñо¿ºËÌÇÌå×é³É£¨×é³É£©ÂѰ׶ÔmRNA·­ÒëµÄÑ¡ÔñÐÔÌṩÁËǰÆÚ»ù´¡£¡£¡£¬£¬£¬²¢ÆÊÎöÁËÈéÏÙ°©Ï¸°ûÄÚÔڵϝÁÆÄÍÒ©»úÖÆ£¬£¬£¬ÎªÕ½Ê¤ÏÈÌìÐÔÖ×Áöϸ°ûÄÍÒ©ÌṩÁËDZÔڵļì²âºÍÖÎÁÆÒ©Îï°Ðµã£¨Í¼ÊÍ£©¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ£º£ºSH3BGRL-PIK3C3/ATG12ͨ·»î»¯µ¼ÖÂÈéÏÙ°©Ï¸°û»¯ÁÆÄÍÒ©µÄ»úÖÆ

ͬÑùµØ£¬£¬£¬Ñо¿ÍŶӻ¹Õ¹ÏÖ¸ÃС·Ö×ÓÌÖÂÛÂѰ×SH3BGRLÔÚ·­ÒëˮƽÉÏÒÖÖÆÖ×Áöϸ°ûÕ³¸½ÂѰ×PFN1ÔÚ·­ÒëˮƽÉϵıí´ï£¬£¬£¬´Ó¶øÔö½øÖ×Áöϸ°û×ªÒÆµÄÌØÕ÷(Oncogene£¬£¬£¬2021£¬£¬£¬Sep; 40(38): 5677-5690£»2020 IF:9.867)£»ËûÃÇ»¹·¢Ã÷SH3BGRL¿ÉÒÔºÍÈéÏÙ°©Ï¸°ûĤÉϵÄHER2ÂѰ×ÊÜÌåÁ¬Ïµ£¬£¬£¬´Ó¶ø²»ÒÀÀµÉú³¤Òò×Ó¼¤»î²¢ÎȹÌϸ°ûĤÉϵÄHER2ÒýÆðHER2°ÐÏòÖÎÁƵÄÏÈÌìÐÔÄÍÒ©(J Exp Clin Cancer Res. 2020 May 7;39(1):81£»2020 IF:11.161)¡£¡£¡£

ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔººÍngµç×ÓÓÎÏ·ÖÐɽҽѧԺÁªºÏ×÷ÓýµÄ²©Ê¿Ñо¿ÉúÕÅÉÛÑôΪ±¾Ñо¿µÄµÚÒ»×÷Õߣ¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚһҽԺת»¯Ò½Ñ§ÖÐÐÄÑîÊñá°Ñо¿Ô±ºÍngµç×ÓÓÎÏ·ÖÐɽҽѧԺÍõº£º£ºÓ½ÌÊÚΪ±¾ÎĵÄÅäºÏͨѶ×÷Õß¡£¡£¡£±¾ÊÂÇé»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðºÍ¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðÏîĿ֧³Ö£¬£¬£¬Í¬Ê±»ñµÃ½ÌÓý²¿×éÖ¯¹¤³ÌÓë¸Éϸ°û¿ÆÑÐÆ½Ì¨µÄ´óÁ¦Ö§³Ö¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£ºhttps://doi.org/10.1080/15548627.2021.2002108

¡¾ÍøÕ¾µØÍ¼¡¿